Rebolledo-García D, Granados-Moreno DL, González-Vargas PO

Language: Spanish
References: 31
Page: 582-593
PDF size: 262.77 Kb.

ABSTRACT

Alcohol withdrawal syndrome is a public health problem of special attention in second level hospitals in Mexico. Classified as a neuropsychiatric condition, the current evidence reflects systemic involvement beyond the central nervous system. The management of these patients is carried out in the internal medicine hospitalization rooms; when the symptoms are severe, it requires a multisystemic approach in the Intensive Care Unit. Although the diagnostic criteria of the American Psychiatric Society have not been modified in the last editions (DSM-4 and 5), treatment during the last decade has been extended by the wide spectrum of therapeutic options in its management. The cost of hospitalization is high due to the multiple accompanying comorbidities found in the alcoholic patient. Therefore, the purpose of this paper is to review the international and national perspective of the different guidelines in the management of the disease, recalling that on the seasoned clinician falls the individualized therapeutic decision in each case.

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. DSM-5. Washington, DC: American Psychiatric Publishing, 2013.

2. McKeon A, Frye MA, Delanty N. The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry 2008;79:854-862.

3. Schuckit MA. Alcohol-use disorders. Lancet 2009;373:492- 501.

4. Gershengorn HB, Wunsch H. The epidemiology of alcohol withdrawal syndrome in United States intensive care units. Am J Respir Crit Care Med 2014;189:A4537.

5. Hernández-Andraca K, Vargas-Ayala G, Cerda-Téllez F, Melchor-López A, Huerta-Ramírez S, Elizalde-Barrera CI. Validación de la escala CIWA en pacientes mexicanos con síndrome de supresión de alcohol. Med Int Mex 2012;28(2):103-111.

6. Ramírez-Velazco DH, Sánchez-Hernández G. Capacidad diagnóstica de las escalas Cushman y AWS para supresión etílica. Med Int Mex 2013;29(1):26-31.

7. Nagy J. Alcohol related changes in regulation of NMDA receptor functions. Current Neuropharmacol 2008;6:39-54.

8. Allgaier C. Ethanol sensitivity of NMDA receptors. Neurochem Int 2002;41(6):377-382.

9. Mayo-Smith MF, Beecher LH, et al. Management of alcohol withdrawal delirium. Arch Intern Med 2004;164:1405- 1412.

10. Lorh RH. Treatment of alcohol withdrawal in hospitalized patients. Mayo Clin Proc 1995;70:777-782.

11. Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs 2014;28:401-410. Epub 2014/05/02.

12. Jesse S, Bråthen G, et al. Alcohol withdrawal syndrome: mechanisms, manifestations and management. Acta Neurol Scand 2017;135:4-16.

13. Awissi DK, Lebrun G, et al. Alcohol withdrawal and delirium tremens in the critically ill: a systematic review and commentary. Intensive Care Med 2013;39:16-30.

14. Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med 2014;371:2109- 13.

15. Goodson CM, Clark BJ, et al. Predictors of severe alcohol withdrawal syndrome: a systematic review and metaanalysis. Alcohol Clin Exp Res 2014;38(10):2664-2677.

16. Khan A, Levy P, DeHorn S, Miller W, Compton S. Predictors of mortality in patients with delirium tremens. Acad Emerg Med 2008;15:788-90.

17. Schmidt KJ, Doshi MR, et al. Treatment of severe alcohol withdrawal. Ann Pharmacother 2016;50(5): 389-401.

18. Maldonado JR, Sher Y, et al. The “Prediction of Alcohol Withdrawal Severity Scale” (PAWSS): Systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol 2014 Jun;48(4):375-90. doi: 10.1016/j.alcohol.2014.01.004.

19. Weintraub SJ. Diazepam in the treatment of moderate to severe alcohol withdrawal. DOI 10.1007/s40263-016- 0403-y.

20. Sachdeva A, Choudhary A, et al. Alcohol withdrawal syndrome: benzodiazepines and beyond. J Clin Diagn Res 2015;9(9):VE01-VE07.

21. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; 3: CD005063.

22. Freynhagen R, Backonja M. Pregabalin for the treatment of drug and alcohol withdrawal symptoms: A comprehensive review. CNS Drugs 2016;30:1191-1200.

23. Ray La, Heydari A, et al. Quetiapine for the treatment of alcoholism: Scientific rationale and review of the literature. Drug Alcohol Rev 2010;29:568-575.

24. Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews 2017. DOI: 10.1002/14651858.CD008502.pub5.

25. Hoy SM, Keating GM. Dexmedetomidine: a review of its use for sedation in mechanically ventilated patients in an intensive care setting and for procedural sedation. Drugs 2011;71:1481-1501.

26. Brotherton AL, Hamilton EP, et al. Propofol for treatment of refractory alcohol withdrawal syndrome: a review of the literature. Pharmacotherapy 2016;36(4):433-442.

27. Glauser T, Shinnar S, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Currents 2016;48-61.

28. Mo Y, Thomas MC, Karras JG Jr. Barbiturates for the treatment of alcohol withdrawal syndrome: a systematic review of clinical trials. J Crit Care 2015, doi: 10.1016/j. jcrc.2015.11.022

29. Gold JA, Rimal B, Nolan A, Nelson LS. A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens. Crit Care Med 2007;35:724-730.

30. Kalabalik J, Sullivan JB. Use of dexmedetomidine in the management of alcohol withdrawal syndrome in critically ill patients. Int J Crit Care Emerg Med 2014;1:1.

31. Stewart R, Perez R, et al. Outcomes of patients with alcohol withdrawal syndrome treated with high-dose sedatives and deferred intubation. Ann Am Thorac Soc 2016;13(2):248-252.